The most played episodes among Podcast App listeners.

1. 1
   Number 1: Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Kline

   Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer. In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Kline, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the emerging role of novel therapies like RAS inhibitors. Key topics include: Overview of current treatment paradigms for metastatic pancreatic cancer Discussion of side effects and patient management strategies The importance of communication and collaboration within the oncology team Insights into the future of pancreatic cancer treatment and the potential of new therapies Whether you're a healthcare professional, a patient, or simply interested in oncology, this episode offers valuable perspectives on delivering compassionate and effective cancer care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #PancreaticCancer, #PartnersInPractice, #RASinhibitors, #OncologyBrothers

   August 06, 2026·20min
   Play
2. 2
   Number 2: Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer

   Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more. Key topics included: An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide The importance of monitoring side effects and strategies to mitigate them Insights from recent studies, highlighting the impact of these medications on patient quality of life A discussion on the role of shared decision-making in treatment options for prostate cancer patients Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers! #ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

   August 17, 2026·25min
   Play
3. 3
   Number 3: Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan

   Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression. In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept, and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification and the potential for improved patient outcomes. The second case featured a 67-year-old woman whose disease has progressed despite initial treatment with luspatercept. Dr. Zeidan shared insights on the next steps, including the use of hypomethylating agents (HMAs) , the role of transplant, and the management of side effects associated with these therapies. Tune in for an informative discussion that not only addressed treatment strategies but also emphasized the importance of patient-centered care and the need for ongoing monitoring and support. Don't forget to like, subscribe, and share your thoughts with us! If there are specific topics or cases you'd like us to cover in future episodes, reach out to us. Episode Highlights: Overview of MDS and its treatment landscape Case discussions on treatment decisions for anemia and disease progression Insights on the use of luspatercept and hypomethylating agents Management of side effects and the importance of patient education Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Thanks for tuning in! We are the Oncology Brothers. #MDS, #MyelodysplasticSyndrome, #HMAs, #HemeMalignancy, #OncologyBrothers

   August 13, 2026·25min
   Play
4. 4
   Number 4: Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann

   Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute. Join us as we explored: The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs The importance of spleen reduction and its correlation with patient outcomes and survival Insights into the side effect profiles of various treatments and the future of myelofibrosis management Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

   September 07, 2026·25min
   Play
5. 5
   Number 5: Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)

   Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET). We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: ⁠https://x.com/oncbrothers⁠ ⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠ Website: ⁠https://oncbrothers.com/⁠ Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers

   September 04, 2026·27min
   Play